GLP-1 fatigue
You are dealing with a symptom and want to know if it is expected.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
Fatigue is in the labelling. It appears in the Wegovy adverse-reaction table at 9–11% depending on the dose against 5% on placebo, and among the reactions Zepbound lists as reported in at least 5% of patients. So it is documented, and it is reported above the placebo rate.
Listed in the prescribing information
Common adverse reactions listed for GLP-1 receptor agonists as a class.
- NauseaMost commonly reported; typically worst after a dose increase.
- DiarrhoeaGastrointestinal effects are the most frequently listed category.
- VomitingReported more often at higher doses.
- ConstipationRelated to slowed gastric emptying.
- Abdominal painListed across the class.
- Injection site reactionsApplies to injectable products only.
- FatigueListed in product labelling.
- HeadacheListed in product labelling.
These products carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Read the full prescribing information for your specific product and discuss it with your prescriber — this summary is not complete and is not a substitute for that document.
What the labels do not do is explain it, and there are at least three candidates they cannot separate: the drug itself, eating substantially less than before, and losing weight quickly. All three arrive at the same time on this treatment, which is precisely why the trials could not disentangle them either.
The reason that distinction is worth caring about: two of those three are things a clinician can check. Intake that has fallen far enough to matter, and the nutritional consequences of rapid loss, are examinable. Fatigue attributed to the drug and left there is fatigue that never gets those checks.
Common questions
- When should I raise it?
- If it is limiting what you can do, or if it arrived alongside anything else. Fatigue plus dizziness, or fatigue with an inability to keep fluids down, is a different presentation from feeling flat.
- Does it settle?
- The labels record how often it was reported, not how long it lasted. They contain nothing on duration in either direction.
- Could it be something checkable?
- Thyroid function and iron status affect energy, are testable, and do not stop being possible because you started a GLP-1. Same reasoning as the hair loss page: timing is not attribution.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
- Saxenda (Liraglutide) prescribing information — Novo Nordisk, label revised 15 June 2026, checked 7 August 2026
- Trulicity (Dulaglutide) prescribing information — Eli Lilly, label revised 25 March 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: glp-1 fatigue · glp 1 tiredness